Halazepam

Halazepam

SCHEMBL78995

O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Halazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP known ✓ O00591 1/20 0.64
GABRD known ✓ O14764 1/20 0.64
GABRA1 known ✓ P14867 1/20 0.64
GABRB1 known ✓ P18505 1/20 0.64
GABRG2 known ✓ P18507 1/20 0.64
GABRB3 known ✓ P28472 1/20 0.64
GABRA5 known ✓ P31644 1/20 0.64
GABRA3 known ✓ P34903 1/20 0.64
GABRA2 known ✓ P47869 1/20 0.64
GABRB2 known ✓ P47870 1/20 0.64
GABRA4 known ✓ P48169 1/20 0.64
GABRE known ✓ P78334 1/20 0.64
GABRA6 known ✓ Q16445 1/20 0.64
GABRG1 known ✓ Q8N1C3 1/20 0.64
GABRG3 known ✓ Q99928 1/20 0.64
GABRQ known ✓ Q9UN88 1/20 0.64
OPRK1 P41145 4/20 1.00
NR1I2 O75469 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
OPRM1 P35372 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Halazepam SCHEMBL29375979 1.00 OPRK1 (1.00) OPRK1NR1I2ADORA3OPRM1TP53
Halazepam SCHEMBL28086644 0.92 OPRK1 (0.85) OPRK1NR1I2ADORA3OPRM1TP53
Halazepam SCHEMBL28086105 0.88 OPRK1 (0.77) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL5379874 0.87 OPRK1 (0.77) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL13352364 0.86 OPRK1 (0.76) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL3249926 0.86 NR1I2 (0.74) OPRK1NR1I2ADORA3OPRM1TP53
Halazepam SCHEMBL17396210 0.85 OPRK1 (0.72) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL5355886 0.85 OPRK1 (0.73) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL3579580 0.85 OPRK1 (0.73) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL5349082 0.85 TP53 (0.84) OPRK1NR1I2ADORA3OPRM1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 10244 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
US-20250375421-A1 METHODS OF USING DMT SHULMAN WILLIAM (US) 2025-12-11 US claimed
US-12396981-B2 Methods of using DMT SHULMAN WILLIAM (US) 2025-08-26 US claimed
US-20250205146-A1 GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION SISSA - SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI (IT) 2025-06-26 US claimed
WO-2025126159-A1 A METHOD FOR TREATING A NEUROLOGICAL DISEASE IN A RECREATIONAL DRUG USER TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-06-19 WO claimed
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 AUSPEX PHARMACEUTICALS LLC 2025-06-05 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
US-20250120962-A1 NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATORS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND 22Q SYNDROME THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2025-04-17 US claimed
WO-1992020328-A2 IMPROVEMENTS IN BENZODIAZEPINE TREATMENT BY CHOLINESTERASE INHIBITORS SNORRASON ERNIR (IS) 1992-11-26 WO claimed
EP-0515301-A2 Improvements in benzodiazepine treatment by cholinesterterase inhibitors Snorrason, Ernir (IS) 1992-11-25 EP claimed
EP-0328282-B1 PHARMACEUTICAL ICI AMERICAS INC. (US) 1992-08-19 EP claimed
EP-0428272-A2 Trifluorobenzodiazepine compounds for use in therapy by intraoral administration Ellinwood, Everett Hews (US) 1991-05-22 EP claimed
US-4925844-A ADMINISTERING 4-AMINO-8-PHENYL-N-PROPYL-3-CINNOLINECARBOXAMIDE ICI AMERICAS INC. (US) 1990-05-15 US claimed
EP-0328282-A2 Pharmaceutical ICI AMERICAS INC. (US) 1989-08-16 EP claimed
EP-0098113-B1 A COMBINATION OF BETA-ADRENOCEPTOR ANTAGONISTS AND ANXIOLYTIC AGENTS AYERST, MCKENNA AND HARRISON INC. (CA) 1986-09-03 EP claimed
US-4595684-A Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof CIBA-GEIGY CORPORATION (US) 1986-06-17 US claimed
EP-0098113-A1 A combination of beta-adrenoceptor antagonists and anxiolytic agents AYERST, MCKENNA AND HARRISON INC. (CA) 1984-01-11 EP claimed
US-4155904-A Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones SCHERING CORPORATION (US) 1979-05-22 US claimed